XBiotech halts all rheumatology research after missing Phase II endpoints
XBiotech’s stock price has taken a hit after it announced a complete halt to its clinical program in rheumatological diseases…
All articles by Joshua Silverwood
Joshua Silverwood
-
-
Arrowhead doses first patient in Phase I/IIa RNA obesity therapy trial
California company Arrowhead Pharmaceuticals has announced that it has dosed the first patient as part of its new Phase I/IIa…
-
BMS sees success in Phase III Sotyktu psoriatic arthritis trials
Bristol Myers Squibb (BMS) has announced positive topline results from two Phase III trials evaluating the efficacy and safety of…
-
JCR Pharmaceuticals doses first patient in paediatric growth hormone trial
Japanese healthcare firm, JCR Pharmaceuticals, has announced that it has dosed the first paediatric patient as part of its Phase…
-
Novo Nordisk takes a hit as CagriSema underperforms in weight loss
Danish mega-company Novo Nordisk has taken a hit after its newest experimental weight loss drug, CagriSema, fell short of expectations…
-
Sorriso Pharma’s UC treatment hits Phase Ib endpoints
Utah biopharma company Sorriso Pharmaceuticals has confirmed its Phase Ib trial of an oral drug for patients with ulcerative colitis…
-
Hansa Biopharma announces success in Guillain-Barré Syndrome trial
Swedish biotechnology firm Hansa Biopharma has announced that its investigational drug imlifidase improved motor function in patients with Guillain-Barré Syndrome…
-
Prothena’s Parkinson’s study fails primary endpoint despite some success
Irish late-stage clinical biotechnology company, Prothena Corporation, has announced results from its Phase IIb study of prasinezumab failed to meet…
-
Tenya Therapeutics sees mixed success in HCM gene therapy trial
San Francisco biotechnology Tenaya Therapeutics has shared “encouraging” data from its first patients in the MyPEAK-1 clinical trial of TN-201,…
-
UCB drops Parkinson’s treatment after ORCHESTRA trial failed all endpoints
Belgian pharmaceutical company UCB is dropping its development of minzasolmin in patients with Parkinson's' disease after the ORCHESTRA study failed…